Overview

* OraSure ( OSUR ) Q3 revenue declines 32% yr/yr, missing analyst expectations

* Adjusted operating income for Q3 beats analyst estimates

* Company repurchased 1.5 mln shares for $5 mln in Q3

Outlook

* Company guides Q4 2025 revenues between $25 mln and $28 mln

* OraSure ( OSUR ) plans new product launches in rapid diagnostics and sample management solutions in 2026

* Company sees strong balance sheet aiding navigation of short-term turbulence

Result Drivers

* FUNDING UNCERTAINTY - Co says some customers face uncertainty in funding for public health programs, impacting core business revenues

* PRODUCT LAUNCHES - Co expects growth from new product launches in rapid diagnostics and sample management solutions next year

* DECLINE IN HIV TEST REVENUE - Diagnostics revenues decreased 34% yr/yr due to lower revenue from HIV tests

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $27.10 $29.13

Revenue mln mln (3

Analysts

)

Q3 Gross 43.50%

Margin

Q3 Beat -$12.70 -$18.05

Adjusted mln mln (2

Operatin Analysts

g Income )

Q3 -$16.10

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for OraSure Technologies Inc ( OSUR ) is $4.75, about 45.9% above its November 4 closing price of $2.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)